One-year anniversary of with volume procurement: the frustrated and the proud coexist

"
Pharmaceutical Network Market Analysis" price reduction, can be said to be the main theme of the pharmaceutical industry in recent yearsOn April 1, 2019, the purchase of the belt was fully rolled out in the "4 plus 7" pilot cities, which opened the domestic centralized procurementBand procurement can be understood as a large-scale "group purchase", that is, clear procurement volume, low-cost winning bid, with volume procurement can be through the market-based bidding between enterprises, play the role of volume-for-price, thereby reducing the price of purchased drugsToday, the band purchase has been implemented for more than a yearWhat is the current sales of varieties included in the collection?recently reviewed the sales of chemical drug terminals in 9 pilot areas (Beijing, Tianjin, Shanghai, Chongqing, Guangzhou, Shenzhen, Chengdu, Shenyang, Xi'an) in 25 band-purchased varieties following the first anniversary of the implementation of the "4 plus 7" band purchaseStructurally, the frustrated and the proud coexistoverall, most of the winning enterprises are proud, its variety market size has increased to varying degreesFor example, the market share of the right metamide injection sinof in Yangzijiang Pharmaceuticals has increased significantly in nine pilot areas, from 0.1% in 2018 to 69.67% in 2019, and the increase in market share in 25 varieties has been significantHuahai Pharmaceuticals' Renopredoral Renopreda oral reprex was closely followed, growing from 0% in 2018 to 68.26% in 2019In addition, the market share growth of Monteshioral oral dispersants and Huiyu Pharmaceuticals' Peimei Quplug injections was also significant, rising from 2.36%, 0.09% to 51.2% and 33.71%, respectivelyindustry analysis, the first sound pharmaceutical industry, Huiyu pharmaceutical and other enterprises before the market share is relatively low, and through the volume procurement in the sub-sector to win the opportunity to bend overtaking, access to a large number of incremental market, the market pattern has also changed significantlybut there are also a few successful companies for the frustratedFor example, AstraZeneca's Giffinib, for example, and Beijing Ted's fluoxodofenest, saw a decline in sales and market shareIn Fiscal 2019, the products of these two companies accounted for 82.62% and 97.38% of the market share in public hospitals in the nine pilot areas, respectively, a decrease of 2.75% and 2.22%, respectivelyIt is reported that AstraZeneca's Giofinib oral resusonant agent is due to the domestic generic drug prices continue to reduce, the latter is because of generic products on the market, the overall size of the "4 plus 7" variety market has declinedFor example, products such as fluoxoxefen, Entikawe, Paroxitin and Renopri have all declined by more than 50% in public hospital sales in nine pilot areasHowever, Yangzijiang right metomy fixed injection sales compared with 2018, sales growth of 2.95 percent, mainly because it is a unique product, the pressure of enterprise price reduction is small, so it shows a trend of increasing volumeindustry points out that while the one-year anniversary of the volume is purchased, the proud and the frustrated coexistBut from the purpose of centralized procurement, from the pilot to expand to gradually normal, the price of drugs is falling, good for patients, especially some long-term medicine patients with chronic diseases, so the purchase of 4 plus 7 belt volume is a good thing for the whole of ChinaHowever, for pharmaceutical enterprises, because most enterprises are facing price reduction and survival pressure, is not conducive to increase innovation investment, so also need the support of relevant supporting policies to build a sustainable and healthy development of the pharmaceutical industry policy environment.